bioAffinity Technologies, Inc. shared a patient case study on September 9, 2025, demonstrating CyPath® Lung's effectiveness in identifying lung cancer in a patient with difficult-to-diagnose ground-glass pulmonary nodules. The patient, with a history of smoking, had an incidentally found ground-glass nodule on a CT scan.
Ground-glass nodules are often challenging to diagnose definitively with standard imaging alone. The CyPath® Lung test provided a 'likely malignancy' result, which prompted further investigation and led to an early diagnosis.
This early detection enabled timely treatment for the patient, highlighting CyPath® Lung's capability to provide crucial diagnostic clarity in complex cases. The ability to identify such nodules at an early stage can significantly improve patient outcomes by facilitating prompt intervention.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.